Reminder: Login to access new features and members-only content!

Register to be a member of our community. Its easy!

Register a new account

Already a member?

Log In here!

Donate

Did you find our content interesting or helpful? Help support the IPFD enhance health, well-being and welfare for dogs everywhere.

Jump to content
  •   Language
  • Sign Up

International Partnership for Dogs - Enhancing Dog Health, Well-Being, and Welfare - Join Us.

Nemaline Myopathy

Breeds

Relevance Rating: Unknown, not evaluated or no evidence for test in this breed

General

Disease Name
Nemaline Myopathy
Mutation
g.52734272 C>A
Test Type
Genetic Disease/Disorder
Details
Nemaline Myopathy causes extreme muscle atrophy and weakness, tremors, and exercise intolerance. Age of symptoms onset from 8 weeks of age. Most dogs are euthanized before one year of age due to poor quality of life.
Details 2
Affected dogs could independently ambulate, had generalized atrophy, and the myopathy was relatively non-progressive... Atrophy of the cervical and dorsal thoracic limb muscles was noted with bilateral hypertrophy of the triceps muscles. Serum creatine kinase (CK) activities were mildly elevated. Electromyography (EMG) revealed spontaneous electrical activity, consisting mainly of fibrillation potentials, within the proximal appendicular muscles of the thoracic limbs and the cervical paraspinal musculature. Motor nerve conduction velocity (MNCV) testing showed a mild decrease in the latency of the tibial and ulnar nerves. Respiratory difficulties were not present. (Evans et al, 2016)
Published
Evans, Jacquelyn M., Melissa L. Cox, Jonathan Huska, Frank Li, Luis Gaitero, Ling T. Guo, Margaret L. Casal, Henk L. Granzier, G. Diane Shelton, and Leigh Anne Clark. "Exome sequencing reveals a nebulin nonsense mutation in a dog model of nemaline myopathy." Mammalian genome: official journal of the International Mammalian Genome Society 27, no. 9-10 (2016): 495-502.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.